Article
Refine
Year of publication
- 2017 (3) (remove)
Document Type
- Article (3) (remove)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- - (3)
- Allogeneic blood (1)
- Allogeneic transfusion (1)
- Blood donation (1)
- Blood safety (1)
- Blood supply (1)
- Blood transfusion (1)
- Demographic change (1)
- Donor research (1)
- Donors (1)
- Gene expression (1)
- Intracellular localization (1)
- Ovarian cancer (1)
- PAI-1 RNA-binding protein 1 (1)
- Plasminogen activator inhibitor 1 (1)
- Red blood cell concentrate (1)
- Transfusion (1)
- Whole blood (1)
- glucose homeostasis (1)
- signal transduction (1)
- trace amine-associated receptor 1 (1)
- variants (1)
- weight regulation (1)
Institute
- Institut für Community Medicine (3) (remove)
Publisher
- S. Karger AG (2)
- Frontiers Media S.A. (1)
Background: The plasminogen activator system plays a key role in ovarian cancer (OC) tumor progression. The plasminogen activator inhibitor type 1 (PAI-1) and the recently identified PAI-1 RNA binding protein 1 (PAI-RBP1) are primary regulators of plasminogen activation and thus are putative biomarkers for OC progression. Methods: One hundred fifty six OC patients were analyzed to identify the presence of PAI-1 and PAI-RBP1 and subsequently correlated to clinicopathological parameters. Primary cells obtained from OC patient samples were applied in fluorescence microscopy analysis for examination of PAI-1 and PAI-RBP1 distribution. Results: PAI-1 and PAI-RBP1 have been found to be predictive markers for OC patients' outcome. PAI-1 levels significantly correlated with volume of ascites, FIGO staging, and lymph node status. PAI-RBP1 expression significantly correlated with age at first diagnosis, histological tumor type, presence of distant metastasis (pM), and recurrence. PAI-1 showed a trend toward association and PAI-RBP1 was significantly associated with progression-free survival. Notably, PAI-1 protein in recurrent OC tissues was exclusively localized in the nucleus. Conclusion: This study has shown that a combination of PAI-1 and PAI-RBP1 may represent novel prognostic factor for OC. Prospective trials are needed.